O'Dwyer, M E <br/><br/>
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.  [electronic resource] 

 -  The Lancet. Oncology  Dec 2000 
 - 207-11 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1470-2045 
<br/><br/><label>Standard No.: </label>10.1016/s1470-2045(00)00149-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Benzamides<br/>Clinical Trials, Phase I as Topic<br/>Disease Models, Animal<br/>Enzyme Inhibitors--pharmacology<br/>Fusion Proteins, bcr-abl--drug effects<br/>Humans<br/>Imatinib Mesylate<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--diagnosis<br/>Piperazines--pharmacology<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrimidines--pharmacology<br/>Sensitivity and Specificity